Cargando…

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

BACKGROUND: Single-agent immunotherapy is currently the recommended second-line therapy for patients with advanced non–small cell lung cancer (NSCLC) without targetable mutations; however, the objective response rate (ORR) remains low. This phase II study evaluated the efficacy of the combination th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yongchang, Song, Lianxi, Zeng, Liang, Xiong, Yi, Liu, Li, Zhou, Chunhua, Yang, Haiyan, Wang, Zhan, Xia, Qing, Jiang, Wenjuan, Xu, Qinqin, Yang, Nong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446552/ https://www.ncbi.nlm.nih.gov/pubmed/36064386 http://dx.doi.org/10.1186/s12885-022-10045-0

Ejemplares similares

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
por: Han, Xiao, et al.
Publicado: (2022)

PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
por: Huang, Zhe, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
por: Zhang, Xiangyu, et al.
Publicado: (2020)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Correction: Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
Publicado: (2023)

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study
por: Jiang, Wenjuan, et al.
Publicado: (2022)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China
por: Han, Xiao, et al.
Publicado: (2022)

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
por: Shi, Yuankai, et al.
Publicado: (2022)

Docetaxel Plus Nedaplatin or Carboplatin as Second-Line Chemotherapy for Advanced Lung Squamous Cell Carcinoma in Real-World Practice: A Single-Center Experience
por: Zhong, Jian, et al.
Publicado: (2023)

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
por: Zhou, Nan, et al.
Publicado: (2023)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study
por: Song, Lianxi, et al.
Publicado: (2023)

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial
por: Lorenzen, S, et al.
Publicado: (2005)

Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
por: Song, Lianxi, et al.
Publicado: (2022)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study
por: Zhang, Zao, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
por: Passildas‐Jahanmohan, Judith, et al.
Publicado: (2021)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
por: Wei, Wei, et al.
Publicado: (2022)

The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer
por: Chen, Gong, et al.
Publicado: (2017)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial
por: Guo, Chengxiang, et al.
Publicado: (2023)

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial
por: Chen, Kaiyan, et al.
Publicado: (2023)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report
por: Zhang, Zhipeng, et al.
Publicado: (2022)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
por: Liu, Linlin, et al.
Publicado: (2023)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study
por: Jiang, Qian, et al.
Publicado: (2019)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hef2c2ktsu03cei96kj3nk81lg